Alcon stock
ALC.SWSIXAlcon Inc., HealthcareISIN CH0432492467
62Score 62 out of 100, Neutral
Price and trend
69 / 100
Price history
−5.9% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 5.1% above it.
Since April 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 10% below its 52-week high. Largest decline in 8 years: 42% (September 2024 to May 2026).
Chart figures for advanced users
- SMA 50$67.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$69.08
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$58.74
- The lowest closing price of the last twelve months.
- Resistance$80.81
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alcon Inc. belongs to the Medical (Specialties) industry (Switzerland) and, with a market value of $35.11B, is the largest of 14 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $10.9B (up 9.9% year on year) and earnings of $1.03B (up 0.8%).
- MEQIRI Score 62 out of 100 (Neutral): rank 243 of 714 in Healthcare, median 53.
Show more
- The P/E is 53.5 (Healthcare sector median 26.7, own median of recent years 41.1).
- Our model puts fair value at $72.68, with the price 1% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 269% of earnings over the last 12 months.Fundamentals 65
Weaknesses
- Richly valuedP/E 53.5, Healthcare sector median 26.7, own median 41.1.Valuation 37
Its standout strengths are stability and momentum, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 61 to 62.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $51.92 and expensive above $121.14 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $109.08 (cash-flow model) and $36.29 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $63.30, at 7.8% it would be $86.79.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 7% on the twelve months before. Revenue has grown solidly since 2015, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating 13%, net 9%.
Debt & balance sheet
latest quarterLow debt, and interest is adequately covered.
Earnings
- Next earnings
- 2 Mar 2027in 110 days
- Last reported
- 10 Nov 2026EPS reported 0.75 (expected 0.71)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 3.45+0.1%
- Revenue
- $10.91B0.0%
- Earnings per share
- 3.9−0.1%
- Revenue
- $11.54B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +1.5%Guidance was raised to core operating margin expansion of 90 to 190 basis points and core EPS growth of 12% to 15%, with sales growth of 5% to 7% continued.
“We are increasing our expected core operating margin expansion to a range of 90 to 190 basis points in constant currency, reflecting the strong first half operating performance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Alcon
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next smaller companies by market value
- STERISSTE $24.89B70
- Shanghai United Imaging Healthcare688271.SS $14.35B53
- Sysmex6869.T $7.83B70
- Ypsomed HoldingYPSN.SW $6.56B76
- Medacta GroupMOVE.SW $2.64B58
- Eckert & ZieglerEUZ.DE $969.93M74
- QuidelOrthoQDEL $817.18M32
- Mesa LaboratoriesMLAB $782.43M58
ETFs that hold Alcon
Held by 118 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers SLI UCITS ETF 1DDXS0 | 3.06% | 0.25% | €581.42M |
| Amundi DJ Switzerland Titans 30 UCITS ETF DistC030 | 2.25% | 0.25% | €237.76M |
| Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc540H | 2.03% | 0.30% | €182.66M |
Show 5 more
| Xtrackers Switzerland UCITS ETF 1DXSMI | 2.00% | 0.30% | €2.88B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 1.88% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 1.87% | 0.18% | €954.9M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 1.84% | 0.46% | €729.65M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 1.84% | 0.18% | €653.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.